The U.S. Department of Justice is expanding the scope of healthcare enforcement in ways that many companies are not fully prepared for. What was once centered on billing fraud and false claims is now shifting toward product safety, regulatory transparency, and emerging healthcare models.
Insights from the DOJ’s 2025 Year in Review and recent enforcement actions show a clear trend: companies are increasingly exposed to liability based on how they develop, report, and market healthcare products, not just how they bill for them.
The End of a Billing-Only Enforcement Era
The DOJ is moving beyond traditional fraud cases and focusing on conduct that affects patient safety and regulatory integrity. This includes FDA reporting compliance, product quality, and transparency in communications with regulators.
Instead of relying solely on the False Claims Act, prosecutors are using broader tools, particularly the Federal Food, Drug, and Cosmetic Act (FDCA), to pursue misconduct that may never involve government reimbursement.
DOJ Healthcare Enforcement Trends in 2025
The DOJ’s report reflects a structural shift in how healthcare cases are investigated and prosecuted.
A New Unit Focused on Health and Safety
The DOJ Fraud Section has created a Health and Safety Unit focused on:
- Misbranded or defective medical products
- Unsafe drugs and devices
- Consumer and patient protection
This signals a sustained push toward corporate accountability in healthcare tied directly to public health outcomes.
Turning Regulatory Missteps Into Criminal Cases
The DOJ is increasingly bringing criminal cases under the FDCA, targeting:
- Failure to report adverse events
- Misleading submissions to the FDA
- Distribution of noncompliant products
These are no longer treated as technical violations—they are being framed as intentional efforts to mislead regulators.
Whistleblowers Move Beyond the False Claims Act
The DOJ has expanded its whistleblower program to capture misconduct outside government programs.
This opens the door to:
- Internal reporting tied to private market activity
- Cases that previously would not have triggered federal enforcement
Telehealth and Digital Care Under the Microscope
The DOJ is paying closer attention to:
- Telehealth regulations and prescribing practices
- Digital health platforms
- Online drug distribution
As these models scale, enforcement is catching up.
Recent Cases That Signal the Shift
Recent enforcement actions show how aggressively these priorities are being applied.
ExThera Medical: Silence Became Fraud
A medical device executive pleaded guilty after failing to report patient deaths linked to a device.
This case stands out because:
- It focused on concealment of safety risks
- It imposed individual criminal liability
- It treated a reporting failure as fraud on the FDA
The takeaway is hard to miss: failure to report can now be prosecuted as intentional deception.
Kimberly-Clark: Testing Shortcuts, Criminal Consequences
Kimberly-Clark resolved allegations tied to manipulated testing and avoidance of required FDA submissions, while continuing to market noncompliant surgical gowns.
This case underscores:
- The legal risk of internal testing decisions
- The DOJ’s focus on regulatory evasion, not just outcomes
- The importance of accurate product representations
Where Enforcement Is Expanding Next: Telehealth and Compounding
Two fast-growing sectors are quickly becoming enforcement priorities.
Telehealth’s Compliance Blind Spots
Regulators are examining:
- Whether prescriptions are medically justified
- Compliance with prescribing rules
- Patient acquisition and marketing practices
Compounded GLP-1 Drugs and the Limits of Flexibility
Compounded versions of drugs like semaglutide are under scrutiny due to:
- Unapproved ingredients or formulations
- Dosing inconsistencies
- Aggressive or misleading online marketing
As supply shortages ease, continued compounding outside permitted conditions may trigger misbranding and adulteration claims.
The New Pressure Points for Healthcare Companies
The risk landscape is shifting faster than many compliance programs.
FDA Reporting Is No Longer a Back-Office Function
Companies should:
- Build reliable adverse event reporting systems
- Ensure rapid escalation of safety issues
- Document how reporting decisions are made
Executive Visibility Is Now a Legal Safeguard
Leadership must understand:
- What risks are being identified internally
- Whether reporting obligations are being met
- How decisions are documented
Business Models Need Legal Stress-Testing
Telehealth and compounding operations should be regularly evaluated against:
- FDA rules
- DOJ enforcement trends
- Internal compliance controls
Silence Could Be More Risky Than Disclosure
Voluntary self-disclosure is increasingly part of the DOJ’s enforcement framework. Early reporting and cooperation can significantly reduce exposure.
Key Enforcement Insights
What is driving the expansion of DOJ healthcare enforcement?
The shift is driven by a broader focus on public health and regulatory integrity. The DOJ is prioritizing product safety, FDA reporting compliance, and transparency, rather than limiting enforcement to billing fraud.
What types of healthcare companies face the highest enforcement risk?
Biotech companies, medical device manufacturers, pharmaceutical firms, telehealth platforms, and compounding pharmacies face increased scrutiny due to their role in product development, distribution, and regulatory compliance.
How does the FDCA increase criminal exposure for healthcare companies?
The Federal Food, Drug, and Cosmetic Act allows prosecutors to pursue criminal charges for misbranded or adulterated products and misleading regulators. When intent to defraud is shown, violations can result in felony liability.
What is the most common compliance gap leading to enforcement today?
Failures in FDA reporting compliance—especially delayed or incomplete disclosure of safety events—are emerging as a major enforcement trigger, with potential criminal consequences for both companies and executives.
What Comes Next: Enforcement Tied to the Entire Product Lifecycle
Healthcare enforcement is becoming more closely tied to how products are developed, tested, marketed, and monitored after launch.
Expect:
- Continued focus on FDA reporting compliance and transparency
- Deeper scrutiny of telehealth regulations and digital health models
- More cases built around executive intent and internal decision-making
- Broader use of criminal statutes beyond traditional fraud
Our Expertise
Juris Law Group advises healthcare, life sciences, and consumer product companies navigating high-risk regulatory environments. Our team has experience handling matters involving FDA reporting compliance, product liability exposure, and government investigations.
We work with clients to assess enforcement risk tied to product development, marketing practices, and post market safety obligations. This includes advising on internal investigations, regulatory disclosures, and defense strategies in DOJ and FDA-related actions.
As enforcement expands beyond traditional billing fraud, we help companies align compliance programs with evolving expectations around transparency, safety, and corporate accountability.
